Silexion Therapeutics Overview
Valuation check: SLXN's ROE is 11668.18%, above the sector sector average of -5.84%.
Get informed when a big investor buys or sells
+ Follow11668.18%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for SLXN is 11668.18%. That is above the sector sector average of -5.84%. Investors often review this figure alongside Silexion Therapeutics's historical trend and sector peers before judging valuation or financial health.
Against its sector companies, SLXN currently prints 11668.18% for ROE, while the sector average sits near -5.84%. That is roughly 199729.9% above the sector mean. Large gaps often invite a closer look at Silexion Therapeutics's growth, margins, and balance sheet.
Return on Equity shows how effectively Silexion Therapeutics converts resources into returns. At 11668.18%, SLXN may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting SLXN's ROE (11668.18%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
